In conclusion, as shown in Figure 10, the current study demonstrated that GPS treatment strongly protected NAFLD against oxidative damage and lipid accumulation which were dependent on activation of the Nrf2 antioxidant pathway for the first time. The gene discussed is NFE2L2; the disease is metabolic dysfunction-associated steatotic liver disease.